Fluicell is an innovative life science company dedicated to delivering single-cell microfluidic research tools and services for scientists worldwide, based in Gothenburg Sweden.

Fluicell was founded in 2012 and provides easy-to-use research solutions in 3d single-cell bioprinting of biological tissues as well as single-cell biology and pharmacology.

Fluicell is a world leader and pioneer in open-volume microfluidics for the life sciences, with customers in leading academic institutions and major pharmaceutical companies. Fluicell’s innovative technologies are supported by a strong IP and patent position. The company is listed on Nasdaq First North Growth Market since April 2018 under the Ticker FLUI.